– UK, Alderley Park – Redx Pharma (LON: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announced the appointment of Dr. Rob Scott to its Board as a Non-Executive Director, with immediate effect.
“We are excited to welcome Rob onto the Redx Board. As we build our portfolio of clinical-stage assets, Rob will bring a clinical development and regulatory perspective to help shape our programmes, particularly in the US where he has been based for almost 30 years. The Board and I look forward to working with Rob to ensure that we continue to grow Redx into a successful biotech company focused on the treatment of cancer and fibrotic disease.” said Board Chair, Dr Jane Griffiths.
The Board is now comprised of eight directors, five of whom, including the Chair, are independent Non-Executive Directors, two shareholder representative Non-Executive Directors and CEO, Lisa Anson.
About Dr. Rob Scott
Dr. Scott brings extensive clinical development and regulatory experience to the Board, having held senior leadership positions in global pharma for over thirty years. Most recently, Dr Scott retired as CMO at AbbVie, where he oversaw 14 major regulatory approvals including Venclexta, Orilissa, Skyrizi and Rinvoq. Recent prior experience includes the roles of VP of Global Development at Amgen and Industry Representative on the US Food and Drug Administration Cardiac and Renal Drug Advisory Committee. Dr Scott is currently on the boards of ArisGlobal, Confo Therapeutics, Draupnir Bio, Windtree Therapeutics and Oncospherix as well as several scientific advisory boards. Dr Scott is a Zimbabwean born physician and a graduate of the University of Cape Town.
Dr Rob Scott said “I am delighted to be joining the Redx Board, especially at a time where there is real momentum with the Company’s cancer and fibrosis assets in the clinic. I look forward to working with the Board as Redx continues to progress its exciting drug candidates through the clinical development process.”
About Redx Pharma Plc
Redx Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx’s lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company’s selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Initial results were reported in October 2021, with full Phase 1 results expected in 2022.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company’s accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis, which AstraZeneca is progressing in Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals.
For more information: https://www.redxpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
